Ειδήσεις: OBESITY TREATMENT | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

24/03 17:16 foxnews.com

Greater weight loss promised by higher-dose Wegovy shot, now approved by FDA

Wegovy FDA approval weight loss higher dose needle‑free pill National Priority Voucher

24/03 03:06 sciencedaily.com

Women over 50 lost 35% more weight with this surprising combo

postmenopausal hormone therapy tirzepatide weight loss cardiometabolic risk personalized medicine

19/03 20:42 marketwatch.com

A high dose of Wegovy helped people lose 21% of their weight. It was just approved.

Wegovy weight loss GLP‑1 Novo Nordisk Lilly obesity treatment

19/03 20:30 gizmodo.com

Python Blood Could Kickstart the Next Big Thing in Weight Loss

python metabolite appetite suppression weight loss GLP‑1 alternative Burmese python human metabolite

19/03 18:21 statnews.com

STAT+: Novo Nordisk’s high-dose Wegovy approved in the U.S.

Novo Nordisk Wegovy high‑dose FDA voucher obesity treatment market share

19/03 09:02 defenseworld.net

Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III

aleniglipron GLP‑1 agonist weight loss Structure Therapeutics ACCESS II oral therapy

19/03 09:02 defenseworld.net

Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III

aleniglipron GLP‑1 agonist weight loss Structure Therapeutics ACCESS II oral therapy

Loading...